Inhibikase Therapeutics, Inc. filings document the disclosure record for a Nasdaq-listed clinical-stage pharmaceutical company developing IKT-001 for pulmonary arterial hypertension. Form 8-K reports cover operating and financial results, Regulation FD materials, clinical and regulatory updates for IMPROVE-PAH, and exhibits furnished with company press releases and corporate presentations.
Proxy and annual-meeting filings address board elections, auditor ratification, equity incentive plan amendments, executive compensation and shareholder voting results. Other disclosures describe the company's common stock, Nasdaq listing, inducement equity awards, material agreements, and capital-structure matters involving common stock and warrant securities.
Inhibikase Therapeutics reported a larger quarterly loss as it advances its lead PAH drug IKT-001 into late-stage development. For the three months ended March 31, 2026, the company posted a net loss of $16.4 million, or $0.10 per share, compared with a $13.7 million loss a year earlier. Research and development expenses were $10.8 million, essentially flat year over year after excluding a prior one-time IPR&D charge, while selling, general and administrative costs rose to $7.4 million, driven mainly by higher stock-based compensation.
Other income increased to $1.5 million on interest from cash and marketable securities. Inhibikase ended the quarter with $170.4 million in cash, cash equivalents and marketable securities and an accumulated deficit of about $159.1 million, and believes this cash is sufficient to fund normal operations for at least 12 months. Operationally, the pivotal global IMPROVE-PAH Phase 3 study is enrolling patients, the first patient was enrolled in April 2026, and the company has secured approval to initiate the trial in 16 countries while pursuing approvals in more than 25. Inhibikase also submitted an Orphan Drug Designation application to the FDA for IKT-001 in PAH.
Inhibikase Therapeutics reported first quarter 2026 results and progress on its Pulmonary Arterial Hypertension program. The company enrolled the first patient in its registrational IMPROVE-PAH Phase 3 study and has obtained regulatory approvals in 16 countries, helped by the EMA’s new FAST-EU initiative.
As of March 31, 2026, cash, cash equivalents and marketable securities were $170.4 million. Net loss was $16.4 million, or $0.10 per share, compared with a net loss of $13.7 million, or $0.15 per share, a year earlier. Research and development expenses were $10.8 million, while selling, general and administrative costs were $7.4 million, both up versus the prior-year quarter.
Inhibikase Therapeutics, Inc. is soliciting proxies for its 2026 virtual annual meeting on June 26, 2026. Stockholders will elect two Class III directors, ratify CohnReznick LLP as auditor, and vote on several governance and compensation matters.
Key items include amending the certificate of incorporation to add Delaware-permitted liability protection for certain officers and expanding the 2020 Equity Incentive Plan by 3,000,000 shares of common stock. Stockholders will also cast advisory votes on executive pay and on whether future pay votes occur every one, two or three years, with the board recommending an annual vote. Common stock outstanding was 132,032,636 shares as of April 27, 2026.
Inhibikase Therapeutics, Inc. is soliciting proxies for its virtual 2026 Annual Meeting on to elect two Class III directors, ratify CohnReznick as auditor, approve an officer exculpation amendment to its charter, and approve a 3,000,000‑share increase to its 2020 Equity Incentive Plan. The Board recommends voting FOR each proposal and for an advisory "one year" frequency on executive compensation votes. Record holders as of April 27, 2026 may vote online using a 12‑digit control number; proxy materials and the 2025 Form 10‑K are available at www.proxydocs.com/IKT.
Inhibikase Therapeutics filed an 8-K to share news that the first patient has been enrolled in its pivotal global Phase 3 IMPROVE-PAH study of IKT-001 for Pulmonary Arterial Hypertension (PAH). This marks a key step in moving the program into late-stage testing.
IKT-001 is a novel oral prodrug of imatinib mesylate, designed to lessen gastrointestinal side effects associated with imatinib. The IMPROVE-PAH trial uses a two-part adaptive Phase 3 design with a 12-week dose‑titration phase to help patients reach the highest tolerable dose.
Part A will enroll approximately 140 patients and measure change in pulmonary vascular resistance at Week 24. Part B will follow seamlessly, enrolling about 346 patients and focusing on change in 6-minute walk distance at Week 24. The study may include up to roughly 180 sites worldwide and allows for sample size re-estimation for Part B based on Part A findings. Inhibikase describes PAH as a progressive, life‑threatening disease affecting about 50,000 Americans and views this single pivotal Phase 3 trial as central to advancing IKT-001 toward potential regulatory review.
Inhibikase Therapeutics provides an annual update focused on its lead oral prodrug, IKT-001, being advanced as a potential disease‑modifying treatment for pulmonary arterial hypertension (PAH). The company has shifted strategic focus to PAH and initiated an adaptive global Phase 3 trial, IMPROVE‑PAH, in two parts across approximately 180 sites.
The filing describes prior bioequivalence work showing IKT‑001 doses that match imatinib exposure, FDA feedback supporting the 505(b)(2) pathway, and plans to seek Orphan Drug Designation. Inhibikase reports global commercialization rights and patent coverage for IKT‑001 extending, if granted and maintained, into a 2033–2045 window.
Recent corporate actions include pausing risvodetinib development, acquiring CorHepta Pharmaceuticals in an all‑stock transaction valued at $15.0 million, and licensing risvodetinib to ABLi Therapeutics with potential development and regulatory milestones up to $47.5 million plus double‑digit royalties. The company also raised $115,000,000 in gross proceeds via a public equity and pre‑funded warrant offering and maintains additional flexibility through a Form S‑3 shelf and at‑the‑market program. Context figures include a reported aggregate non‑affiliate market value of common stock of $127.3 million as of June 30, 2025, and 132,032,636 shares outstanding as of March 20, 2026.
Inhibikase Therapeutics reported a larger net loss for 2025 as it advanced its lead Pulmonary Arterial Hypertension program into a global pivotal Phase 3 trial called IMPROVE-PAH. Net loss was $48.3 million, or $0.49 per share, compared with $27.5 million, or $1.16 per share in 2024.
Research and development expenses rose to $29.8 million, including a $7.4 million non-cash write-off of in-process R&D and $2.5 million of stock-based compensation tied to the February 2025 CorHepta acquisition. Selling, general and administrative expenses increased to $23.6 million, including $1.0 million of severance from senior executive transitions.
Cash, cash equivalents and marketable securities were $178.8 million as of December 31, 2025, up from $97.5 million a year earlier, supported by $107.6 million of net proceeds from issuing common stock, pre-funded warrants and warrants. The company highlighted ongoing regulatory submissions in more than 20 countries and active enrollment in its single pivotal Phase 3 PAH study.
Inhibikase Therapeutics director Vincent Aurentz forfeited 255,299 shares of common stock back to the company. These shares had been received as part of the CorHepta Pharmaceuticals acquisition and were subject to forfeiture if a milestone was not met by the first anniversary of the February 21, 2025 closing date.
On February 21, 2026, the milestone was determined not to have been achieved, triggering the return of all 255,299 shares to the issuer at no cost. After this issuer disposition, Aurentz directly holds 510,596 shares of Inhibikase Therapeutics common stock.
Inhibikase Therapeutics executive Cabell Christopher reported the forfeiture of 338,282 shares of common stock back to the company. These shares had been received as part of the CorHepta Pharmaceuticals acquisition completed on February 21, 2025, but were subject to a milestone that had to be met by the first anniversary of that closing date.
On February 21, 2026, the milestone was determined not to have been achieved, causing all 338,282 shares to be returned to the issuer for no consideration. Following this disposition to the issuer, Christopher directly holds 676,564 shares of Inhibikase common stock.